{"id":"metformin-background-drug","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)"},{"rate":"3–5","effect":"Metallic taste"},{"rate":"10–30","effect":"Vitamin B12 deficiency"},{"rate":"<0.1","effect":"Lactic acidosis (rare, in renal impairment)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Metformin is a biguanide that primarily works by decreasing gluconeogenesis in the liver and enhancing peripheral glucose uptake and utilization. It activates AMPK, a key metabolic regulator, which suppresses mTORC1 signaling and reduces hepatic glucose output. Additionally, metformin may improve insulin sensitivity in muscle and adipose tissue, making it effective for glycemic control in type 2 diabetes.","oneSentence":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:56.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Prediabetes (prevention of progression to type 2 diabetes)"},{"name":"Polycystic ovary syndrome (PCOS)"}]},"trialDetails":[{"nctId":"NCT04596631","phase":"PHASE3","title":"A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-02","conditions":"Diabetes Mellitus, Type 2","enrollment":132},{"nctId":"NCT07057479","phase":"PHASE3","title":"Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin","status":"WITHDRAWN","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2026-09","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":""},{"nctId":"NCT05478252","phase":"PHASE3","title":"A Research Study to Compare Two Semaglutide Medicines in People With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2022-08-03","conditions":"Diabetes Mellitus, Type 2","enrollment":388},{"nctId":"NCT05162014","phase":"","title":"To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-20","conditions":"Diabetes Mellitus, Type 2","enrollment":494679},{"nctId":"NCT06218342","phase":"PHASE4","title":"Henagliflozin in Relieving Type 2 Diabetes With Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-02-15","conditions":"Type 2 Diabetes, Non-Alcoholic Fatty Liver Disease","enrollment":156},{"nctId":"NCT02856113","phase":"PHASE3","title":"Phase 3 Alogliptin Pediatric Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-10-14","conditions":"Diabetes Mellitus, Type 2","enrollment":152},{"nctId":"NCT03748810","phase":"","title":"Head-to-head Comparison of Empagliflozin and Dapagliflozin","status":"COMPLETED","sponsor":"Chungbuk National University Hospital","startDate":"2016-01-01","conditions":"Type2 Diabetes","enrollment":600},{"nctId":"NCT02803918","phase":"PHASE1","title":"A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-05-17","conditions":"Type 2 Diabetes Mellitus","enrollment":23},{"nctId":"NCT02836704","phase":"PHASE4","title":"Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-09","conditions":"Diabetes Mellitus, Type 2","enrollment":892},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT04039503","phase":"PHASE3","title":"A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-08-30","conditions":"Type 2 Diabetes","enrollment":475},{"nctId":"NCT03770728","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-01","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT03684642","phase":"PHASE3","title":"Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-09-26","conditions":"Type 2 Diabetes Mellitus","enrollment":908},{"nctId":"NCT02597101","phase":"PHASE2","title":"Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes","status":"COMPLETED","sponsor":"Nick Giannoukakis, PhD","startDate":"2015-11","conditions":"Type 2 Diabetes Mellitus, Insulin Resistance","enrollment":14},{"nctId":"NCT02926950","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2016-11","conditions":"Type 2 Diabetes Mellitus","enrollment":518},{"nctId":"NCT03285594","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-09-15","conditions":"Type 2 Diabetes Mellitus","enrollment":571},{"nctId":"NCT03066830","phase":"PHASE3","title":"Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2017-02-24","conditions":"Type 2 Diabetes Mellitus","enrollment":507},{"nctId":"NCT03640221","phase":"PHASE4","title":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT04029272","phase":"PHASE4","title":"Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-07-20","conditions":"Polycystic Ovary Syndrome","enrollment":80},{"nctId":"NCT02305381","phase":"PHASE3","title":"Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-12-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":397},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT02791490","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-06-16","conditions":"Type 2 Diabetes Mellitus","enrollment":458},{"nctId":"NCT02231021","phase":"PHASE4","title":"The Practical Evidence of Antidiabetic Combination Therapy in Korea","status":"COMPLETED","sponsor":"Kun-Ho Yoon","startDate":"2014-09","conditions":"Type 2 Diabetes Mellitus","enrollment":216},{"nctId":"NCT01819129","phase":"PHASE3","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":881},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02532855","phase":"PHASE3","title":"A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-20","conditions":"Type 2 Diabetes Mellitus","enrollment":614},{"nctId":"NCT02411825","phase":"PHASE1","title":"Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-03","conditions":"Type 2 Diabetes Mellitus","enrollment":76},{"nctId":"NCT02429258","phase":"PHASE4","title":"Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-05","conditions":"Type II Diabetes","enrollment":226},{"nctId":"NCT02058160","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":736},{"nctId":"NCT01798706","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Type 2 Diabetes","enrollment":350},{"nctId":"NCT01476475","phase":"PHASE2","title":"Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":323},{"nctId":"NCT02274740","phase":"PHASE2","title":"Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-04","conditions":"Type II Diabetes Mellitus","enrollment":2},{"nctId":"NCT01768559","phase":"PHASE3","title":"Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-01","conditions":"Type 2 Diabetes","enrollment":894},{"nctId":"NCT01933672","phase":"PHASE1","title":"Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10","conditions":"Type 2 Diabetes Mellitus","enrollment":33},{"nctId":"NCT02749032","phase":"PHASE1","title":"Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion","status":"COMPLETED","sponsor":"Michael A. Nauck","startDate":"2011-11","conditions":"Type 2 Diabetes","enrollment":24},{"nctId":"NCT02366377","phase":"PHASE1","title":"The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2015-02","conditions":"Type 2 Diabetes Mellitus","enrollment":168},{"nctId":"NCT01204294","phase":"PHASE3","title":"Comprehensive Add on Study in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-09","conditions":"Diabetes Mellitus, Type 2","enrollment":574},{"nctId":"NCT00990444","phase":"PHASE1, PHASE2","title":"A Two Part Study of Peroral Insulin in Type 2 Diabetes","status":"SUSPENDED","sponsor":"Bows Pharmaceuticals AG","startDate":"2009-09","conditions":"Diabetes Mellitus","enrollment":32},{"nctId":"NCT00998686","phase":"PHASE3","title":"Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin","status":"TERMINATED","sponsor":"Phenomix","startDate":"2009-11","conditions":"Type 2 Diabetes Mellitus","enrollment":650},{"nctId":"NCT00850239","phase":"PHASE3","title":"Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin","status":"TERMINATED","sponsor":"Phenomix","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":700}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Metformin (Background drug)","genericName":"Metformin (Background drug)","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK). Used for Type 2 diabetes mellitus, Prediabetes (prevention of progression to type 2 diabetes), Polycystic ovary syndrome (PCOS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}